RECEIVED. SECRETARY OF THE SENATE

04 AUG 16 AM 11: 30

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Registrant Name The Harbour Group, LLC				
Address Check if different the	an previously reported 05			
Principal Place of Business (if differe	ent from line 2)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************	
City: Washington	State/Z	p (or Country) D.C. 2	0007	
. Contact Name	Telephone	E-mail (o	ptional)	5. Senate ID#
Joel Johnson	(202) 295-8787			6663
. Client Name	***************************************		1,000011100+11-10+10011	6. House ID#
Pharmaceutical Research and Ma	anufacturers of America (PhRMA)		•	3563
Check if this filing amends a p	n Report 🗖 🗢 Termination	Date		11. No Lobbyin
Check if this filing amends a p	n Report 🗖 🗢 Termination	eport Date		11. No Lobbying
Check if this filing amends a p O. Check if this is a Termination INCOME OR EXPERMANDED 12. Lobby	n Report □ ⇒ Termination NSES - Complete Either ing Firms	DateLine 12 OR Line 1	13. Organiz	ations
Check if this filing amends a p Check if this is a Termination INCOME OR EXPERMANDED 12. Lobby INCOME relating to lobbying	n Report □ ⇒ Termination NSES - Complete Either ing Firms	eport Date	13. Organiz	ations
Check if this filing amends a positive of the control of the contr	n Report □ ⇒ Termination NSES - Complete Either ing Firms	DateLine 12 OR Line 1	13. Organiz	ations
Check if this filing amends a positive of the content of the conte	n Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting	Date Line 12 OR Line 1 EXPENSES relating period were: Less than \$10,000	13. Organiz to lobbying act	ations
Check if this filing amends a positive of the content of the conte	n Report □ ⇒ Termination NSES - Complete Either ing Firms	EXPENSES relating period were: Less than \$10,000 C \$10,000 or more	13. Organiz 3 to lobbying act	eations tivities for this representations
Check if this filing amends a positive of the content of the conte	NSES - Complete Either ing Firms activities for this reporting \$\frac{\$140,000.00}{\text{lncome (nearest \$20,000)}}\$	Date Line 12 OR Line 1 EXPENSES relating period were: Less than \$10,000	13. Organiz 3 to lobbying act	eations tivities for this repenses (nearest \$20, eck box to indicate
Check if this filing amends a poly. Check if this is a Termination INCOME OR EXPERITURE 12. Lobby INCOME relating to lobbying speriod was: Less than \$10,000 \$10,000 or more \$\frac{1}{2} \infty \$5\$ Provide a good faith estimate, reof all lobbying related income	NSES - Complete Either ing Firms activities for this reporting \$\frac{\$140,000.00}{\text{lncome}}\$ complete Either ing Firms activities for this reporting	EXPENSES relating period were: Less than \$10,000 [\$10,000 or more]	13. Organiz 3 to lobbying act	penses (nearest \$20, eck box to indicate for description of
INCOME relating to lobbying period was: Less than \$10,000 \$10,000 or more Provide a good faith estimate, re	NSES - Complete Either ing Firms activities for this reporting \$\frac{\$140,000.00}{\text{lncome (nearest \$20,000)}}\$ counded to the nearest \$20,000, afrom the client (including all any other entity for lobbying)	EXPENSES relating period were: Less than \$10,000 \$10,000 or more 14. REPORTING Maccounting method. Method A. Rep Method B. Rep	13. Organizes, to lobbying act	penses (nearest \$20, eck box to indicate for description cusing LDA define under section 60

Signature /		
Printed Name and Title	Joel Johnson, Managing Director	
LD-2 (REV. 6/98)		Ρ.

Registrant Name	The Harbour Group, LLC	Client Name	Pharmaceutical Research and Manufacturers of
engaged in lobbying		ng the reporting pe	reflect the general issue areas in which the re riod. Using a separate page for each code,
15. General issue as	rea code PHA (one	e per page)	
16. Specific lobbying	ng issues		
Matters affecting	the pharmaceutical industry an	d pharmaceutical reso	earch.
17. House(s) of Co	ongress and Federal agencies	s contacted	Check if None
U.S. Senate	Representatives individual who acted as a lo	hhvist in this issue	2763
10. Ivaille of Cach	Name		Covered Official Position (if applicable)
Joel Johnson	V		
Mary Ann Chaffee			gislative Director for Senator Zell Miller
Kimberly James			

*******************************	***************************************		***************************************

19. Interest of each	foreign entity in the specific is	sues listed on line 16	above
Signature	Filing #62f09efb-7ef4-4e73-92	22b-b5dac9f48089 -	Page 3 of 8

		1	,
Printed Name and Title_	Joel Johnson, Managing Director		l

Form LD-2 (Rev.6/98)

Page _

Registrant Name	The Harbour Group, LLC	Client Name	Pharmaceutical Research and Manufacturers
engaged in lobbying		g the reporting pe	reflect the general issue areas in which the reriod. Using a separate page for each code
15. General issue a	rea code MMM (one	per page)	
16. Specific lobbyi			
Maπers aπecung	the pharmaceutical industry and	pnarmaceuticai res	earcn.
17. House(s) of Co	ongress and Federal agencies	contacted	☐ Check if None
U.S. Senate	Representatives individual who acted as a lot	shvist in this issue	2782
18. Name of each	Name	boyist in this issue	Covered Official Position (if applicable)
Joel Johnson	Name		
Mary Ann Chaffee			gislative Director for Senator Zell Miller
Kimberly James		••••••	
***************************************		***************************************	
***************************************	•		······
***************************************	***************************************		***************************************

19. Interest of each	foreign entity in the specific iss	l sues listed on line 10	6 above
Signature	Filing #62f09efb-7ef4-4e73-922	2b-b5dac9f48089 -	Date \$ 204

Form LD-2 (Rev.6/98)

Page _

Registrant Name	The Harbour Group, LLC	Client Name	Pharmaceutical Research and Manufacturers of
engaged in lobbying		g the reporting pe	eflect the general issue areas in which the reriod. Using a separate page for each code
15. General issue a	rea code HCR (one	per page)	
16. Specific lobbyi			
Matters affecting	the pharmaceutical industry and	pharmaceutical res	earcn.
17. House(s) of Co	ongress and Federal agencies	contacted	☐ Check if None
U.S. Senate	Representatives individual who acted as a lol	obyist in this issue	area
	Name		Covered Official Position (if applicable)
Joel Johnson			
Mary Ann Chaffee Kimberly James		Le	gislative Director for Senator Zell Miller

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			

19. Interest of each	foreign entity in the specific is:	sues listed on line 16	Date 8/12/04

Filing #62f09efb-7ef4-4e73-922b-b5dac9f48089 - Page 7 of 8

- 1
- 1

Printed Name and Title Joel Johnson, Managing Director

Form LD-2 (Rev.6/98)

Page .